| Literature DB >> 33208929 |
Enrico Brunetta1,2, Marco Folci1,2, Barbara Bottazzi1, Maria De Santis1, Giuseppe Gritti3, Alessandro Protti1,2, Sarah N Mapelli1, Stefanos Bonovas1,2, Daniele Piovani1,2, Roberto Leone1, Ilaria My1,2, Veronica Zanon1, Gianmarco Spata1, Monica Bacci1, Domenico Supino2, Silvia Carnevale2, Marina Sironi1, Sadaf Davoudian1, Clelia Peano1,4, Francesco Landi3, Fabiano Di Marco5,6, Federico Raimondi5, Andrea Gianatti7, Claudio Angelini1, Alessandro Rambaldi8,9, Cecilia Garlanda10,11, Michele Ciccarelli12, Maurizio Cecconi13,14, Alberto Mantovani15,16,17.
Abstract
Long pentraxin 3 (PTX3) is an essential component of humoral innate immunity, involved in resistance to selected pathogens and in the regulation of inflammation1-3. The present study was designed to assess the presence and significance of PTX3 in Coronavirus Disease 2019 (COVID-19)4-7. RNA-sequencing analysis of peripheral blood mononuclear cells, single-cell bioinformatics analysis and immunohistochemistry of lung autopsy samples revealed that myelomonocytic cells and endothelial cells express high levels of PTX3 in patients with COVID-19. Increased plasma concentrations of PTX3 were detected in 96 patients with COVID-19. PTX3 emerged as a strong independent predictor of 28-d mortality in multivariable analysis, better than conventional markers of inflammation, in hospitalized patients with COVID-19. The prognostic significance of PTX3 abundance for mortality was confirmed in a second independent cohort (54 patients). Thus, circulating and lung myelomonocytic cells and endothelial cells are a major source of PTX3, and PTX3 plasma concentration can serve as an independent strong prognostic indicator of short-term mortality in COVID-19.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33208929 DOI： 10.1038/s41590-020-00832-x
Source DB: PubMed Journal: Nat Immunol ISSN： 1529-2908 Impact factor: 25.606